中国实用神经疾病杂志
中國實用神經疾病雜誌
중국실용신경질병잡지
CHINESE JOURNAL OF PRACTICAL NERVOUS DISEASES
2014年
20期
18-19
,共2页
郑积华%周娟%谢波%徐志勇%英娟%林金容%张为民
鄭積華%週娟%謝波%徐誌勇%英娟%林金容%張為民
정적화%주연%사파%서지용%영연%림금용%장위민
吉非替尼%非小细胞肺癌%脑转移%全脑放疗
吉非替尼%非小細胞肺癌%腦轉移%全腦放療
길비체니%비소세포폐암%뇌전이%전뇌방료
Gefitinib%Non-small cell lung cancer%Brain metastases%Whole brain radiotherapy
目的:探讨吉非替尼对EG FR突变(+)非小细胞肺癌脑转移预后的影响。方法回顾性分析我院收治的70例EGFR突变(+)非小细胞肺癌脑转移患者的临床资料,根据治疗方法不同分为治疗组和对照组各35例,其中对照组给予常规全脑放疗,治疗组在对照组的基础上给予吉非替尼治疗,比较2组临床效果和不良反应发生情况。结果治疗后治疗组有效率48.57%,显著高于对照组的34.28%( P<0.05);治疗组疾病控制率77.14%,显著高于对照组的60.00%( P<0.05);治疗组C R率17.14%,显著高于对照组的8.57%,治疗组PD率22.86%,显著低于对照组的40.00%( P<0.05);治疗组不良反应发生率45.71%,对照组42.86%,2组比较无显著差异( P>0.05)。结论吉非替尼联合全脑放疗治疗 EG FR突变(+)非小细胞肺癌脑转移患者不良反应小,临床效果显著。
目的:探討吉非替尼對EG FR突變(+)非小細胞肺癌腦轉移預後的影響。方法迴顧性分析我院收治的70例EGFR突變(+)非小細胞肺癌腦轉移患者的臨床資料,根據治療方法不同分為治療組和對照組各35例,其中對照組給予常規全腦放療,治療組在對照組的基礎上給予吉非替尼治療,比較2組臨床效果和不良反應髮生情況。結果治療後治療組有效率48.57%,顯著高于對照組的34.28%( P<0.05);治療組疾病控製率77.14%,顯著高于對照組的60.00%( P<0.05);治療組C R率17.14%,顯著高于對照組的8.57%,治療組PD率22.86%,顯著低于對照組的40.00%( P<0.05);治療組不良反應髮生率45.71%,對照組42.86%,2組比較無顯著差異( P>0.05)。結論吉非替尼聯閤全腦放療治療 EG FR突變(+)非小細胞肺癌腦轉移患者不良反應小,臨床效果顯著。
목적:탐토길비체니대EG FR돌변(+)비소세포폐암뇌전이예후적영향。방법회고성분석아원수치적70례EGFR돌변(+)비소세포폐암뇌전이환자적림상자료,근거치료방법불동분위치료조화대조조각35례,기중대조조급여상규전뇌방료,치료조재대조조적기출상급여길비체니치료,비교2조림상효과화불량반응발생정황。결과치료후치료조유효솔48.57%,현저고우대조조적34.28%( P<0.05);치료조질병공제솔77.14%,현저고우대조조적60.00%( P<0.05);치료조C R솔17.14%,현저고우대조조적8.57%,치료조PD솔22.86%,현저저우대조조적40.00%( P<0.05);치료조불량반응발생솔45.71%,대조조42.86%,2조비교무현저차이( P>0.05)。결론길비체니연합전뇌방료치료 EG FR돌변(+)비소세포폐암뇌전이환자불량반응소,림상효과현저。
Objective To investigate the effects of gefitinib on the prognosis of patients with non-small cell lung cancer brain metastases. Methods The clinical data of 70 patients with non-small cell lung cancer brain metastases in our hospital were retrospectively analyzed. Patients were divided into the treatment group (n=35 ,treated with whole brain radiotherapy ) and the control group (n=35 ,treated with whole brain radiotherapy combined with gefitinib ) according to the different treat-ment methods. The curative effects and adverse reactions were compared. Results The efficiency (48.57% ) ,disease control rate (77.14% ) and CR patients (17.14% ) of treatment group were higher than these of control group (34.28% ,60.00% and 8.57% ) ,respectively ;The PD rate (22.86% ) of treatment group was lower than that of control group ;The adverse reaction incidence between two groups had no significant difference. Conclusion Gefitinib combined with whole brain radiotherapy have less toxic side effects and better curative effect on patients with non-small cell lung cancer brain metastases.